Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo

Print E-mail
By Staff and Wire Reports   
Friday, 19 December 2014 08:49
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada.
Read more...
 

When Considering Cell Therapy Investments - Not All Cells Are the Same Q&A with Zami Aberman, Pluristem Therapeutics

Print E-mail
By M.E.Garza   
Wednesday, 17 December 2014 19:54
BioMedReports.com’s editor, M.E. Garza, spoke with Pluristem CEO, Zami Aberman, a leading developer of placenta-based cell therapy products, regarding clear differentiators between cell therapies and why the cell manufacturing process is key. 
Read more...
 

Wedbush Securities' David Nierengarten on Genetic Cures for Disease: Impossible Dream Come True?

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 11 December 2014 13:23

 

Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients.

Read more...
 

Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal

Print E-mail
By George S. Mack of The Life Sciences Report   
Friday, 05 December 2014 08:56

Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his clinical experience to the readiness of physicians and patients to adopt new therapies.

Read more...
 

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound

Print E-mail
By Josh Gee   
Wednesday, 19 November 2014 09:56

When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses.

Read more...
 

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak

Print E-mail
By Steve Brozak   
Friday, 14 November 2014 00:22
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report.
Read more...
 

Enanta Pharmaceutical's review slated for late December

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 11:27

Enanta Pharmaceutical, Inc, (NASDAQ:ENTA) recently announced that their collaborator Abbvie’s New Drug Application for an interferon-free regimen had been acknowledged by U.S. Food and Drug Administration. The NDA for acceptance of this regimen was submitted on April 21, 2014. The BioMedReports FDA Calendar shows a date for review on December 21, 2014.

Read more...
 

Pozen’s PA8140/PA32540 Tablets Get Another Look

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:20

As you may know, POZEN Inc. (NASDAQ: POZN), gets another chance for a New Drug Application reevaluation after their previous NDA was not accepted due to the issues indicated at some stage in an inspection of the production facility creating an essential constituent necessary for the production of the firm's PA8140/PA32540 Tablets.

Read more...
 

Closer Look: Cubist Pharmaceuticals' New Antibiotic Contender

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 10:14

Cubist Pharmaceuticals (NASDAQ:CBST) previously announced that new antibiotic Ceftolozane has a new drug application which is being out through the steps by the Food and Drug Administration under a priority review, moreover, the FDA has issued a drug user fee act (PDUFA) date of December 21, 2014.

Read more...
 

BiorCryst’s Peramivir PDUFA Date Approaching

Print E-mail
By Dr. Amna Sheikh   
Tuesday, 11 November 2014 09:05

 As you may know, BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) submitted New Drug Application with U.S Food and Drug Administration (FDA) for approval of Peramivir in U.S. The same drug has already been approved in Korea and Japan for treatment of acute influenza.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 49

Newsletter

BioMedReports Bone loss drugs may help prevent endometrial cancer http://t.co/Se1b6YF9UM
6hreplyretweetfavorite
BioMedReports U.S. FDA approves AbbVie all-oral hepatitis C treatment... http://t.co/oZCrnjc9km
BioMedReports FDA grants accelerated approval to AstraZeneca's ovary cancer drug... http://t.co/XxwyJeQVzN